Swiss Medendi

The administration of hazardous therapies such as chemotherapy often involves risks of vein damage, leading to significant complications like necrosis and chemical phlebitis. Swiss Medendi SA, addresses this unmet medical need with its innovative single-use infusion device, designed to protect patients’ vessels using proprietary drug-to-blood diffusion technology. Focused on cancer treatments, the device aims to reduce infusion-related injuries, improving patient safety.